Theravance Biopharma announced an organizational restructuring to align the company around its COPD product YUPELRI after its Phase 3 CYPRESS study of ampreloxetine failed to meet the primary endpoint. The company plans to wind down the ampreloxetine program, eliminate its R&D function and significantly reduce G&A, cutting operating expenses by about 60%, or roughly $70 million annually, with full run-rate savings expected by the third quarter of 2026. The changes are expected to affect about half of the workforce and generate approximately $60 million to $70 million in annualized cash flow starting in Q3 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theravance Biopharma Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF00048) on March 03, 2026, and is solely responsible for the information contained therein.